$12.82
+0.04 (+0.31%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SMMT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 3 with posted results
Held by 13 tracked-famous managers (Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., CITADEL ADVISORS LLC, Squarepoint Ops LLC, +8 more) · FINRA short interest 8.9 days to cover (settled 2026-07-31) · insider 90d: 6 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608Overall Survival (OS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: Ivonescimab Injection, Pembrolizumab Injection | Non-Small Cell Lung Cancer | 1,600 | 2028-12-31 | in 865 d | 2026-04-30 |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerNCT07228832PFS by IRRC based on RECIST v1.1Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Drug: Ivonescimab Injection, Drug: Bevacizumab Injection | Metastatic Colorectal Cancer (CRC) | 600 | 2028-05-31 | in 651 d | 2026-08-04 |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514Overall Survival (OS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: Ivonescimab Injection, Pembrolizumab Injection | Non-Small Cell Lung Cancer | 780 | Apr 2028 | ≤ 620 d | 2026-08-19 |
| Phase III Study of AK112 for NSCLC PatientsNCT06396065Progression-free survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: AK112 Injection, Placebo Injection | Non-Squamous Non-small Cell Lung Cancer | 420 | 2025-04-12actual | — | 2026-07-28 |
| Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile InfectionNCT03595553results2023-03-03Number of Participants With Sustained Clinical Response (SCR) Defined as Clinical Response and no Recurrence of CDI Through 30 Days Post End of Treatment (EOT).Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ridinilazole, Vancomycin | Clostridioides Difficile Infection | 759 | 2021-11-17actual | — | 2023-03-03 |
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent SubjectsNCT04802837results2023-08-21Incidence and Severity of Treatment-emergant Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ | Phase 3 | Terminatedsponsor's stated reason: SMT19969-C006 study was terminated in alignment with corporate decision to pursue further development of drug candidate with a partner. | Drug: Ridinilazole, Vancomycin | Clostridioides Difficile Infection | 2 | 2021-09-17actual | — | 2023-08-21 |
| Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)NCT02858362results2020-01-02Change From Baseline in Magnetic Resonance Spectroscopy (MRS) Fat Fraction (FF) for Leg MusclesNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated due to lack of efficacy in Cohorts 1 and 2. | Drug: Ezutromid | Duchenne Muscular Dystrophy | 43 | 2018-04-11actual | — | 2020-01-02 |
| A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)NCT02784002Number of treatment emergent adverse events (AEs) and serious adverse events (SAEs) to evaluate safety and tolerabilityRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Ridinilazole, Fidaxomicin | Clostridium Difficile Infection | 27 | Aug 2016actual | — | 2017-10-12 |
| A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)NCT02092935Evaluate the clinical outcome by assessment of sustained clinical responseRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: SMT19969, Vancomycin | Clostridium Difficile Infection | 100 | Oct 2015actual | — | 2016-10-20 |
| Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced DietNCT02383511Pharmacokinetic parameters at different dose levels of SMT C1100Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: SMT C1100, SMT C1100, SMT C1100 | Muscular Dystrophy, Duchenne | 12 | Aug 2015actual | — | 2015-08-26 |
| A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)NCT02056808Safety and tolerabilityOpen-label · Treatment | Phase 1 | Completed | Drug: SMT C1100 | Duchenne Muscular Dystrophy | 12 | May 2014actual | — | 2014-08-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19